Unveiling 10 Analyst Insights On Integra Lifesciences
Portfolio Pulse from Benzinga Insights
In the past three months, 10 analysts have rated Integra Lifesciences (NASDAQ:IART), with a mix of bullish and bearish perspectives. The average 12-month price target is $25.1, down from $27.11. Recent analyst actions include several downgrades and lowered price targets, reflecting changing market conditions and company performance.
October 01, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Integra Lifesciences has received mixed analyst ratings, with a recent trend towards downgrades and lowered price targets. The average 12-month price target has decreased to $25.1, indicating cautious sentiment among analysts.
The article highlights a trend of downgrades and lowered price targets for Integra Lifesciences, with the average target dropping from $27.11 to $25.1. This suggests a negative short-term outlook as analysts adjust their expectations downward.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100